A protein called GDNF can repair eye damage caused by diabetes by activating cellular repair pathways and reducing stress inside cells, according to a 2026 study in Investigative Ophthalmology and Visual Science. In diabetic mice, GDNF injected near the eye accelerated corneal healing, stimulated nerve regrowth, and restored eye sensitivity. Gram Research analysis shows this treatment works by reactivating the PI3K/AKT signaling pathway, which reduces a type of cellular stress called endoplasmic reticulum stress that diabetes causes. While these results are promising, human clinical trials are still needed before this therapy becomes available to patients.
According to Gram Research analysis, scientists discovered that a protein called GDNF can help repair eye damage caused by diabetes. In this 2026 study published in Investigative Ophthalmology and Visual Science, researchers tested GDNF on both human eye cells in the lab and diabetic mice. The treatment worked by activating a specific cellular pathway that reduces stress inside cells and helps damaged tissue regrow. When GDNF was injected near the eye, it sped up healing of the cornea (the clear front part of the eye) and helped restore nerve sensitivity. This finding could lead to new treatments for diabetic eye problems that currently affect millions of people worldwide.
Key Statistics
A 2026 study published in Investigative Ophthalmology and Visual Science found that GDNF treatment restored impaired cell growth and movement in human corneal cells exposed to diabetic conditions and significantly reduced cell death caused by high glucose and fat stress.
In diabetic mice, subconjunctival GDNF injection expedited corneal epithelial restoration, stimulated subbasal nerve regrowth, and rescued corneal sensitivity that had been lost due to diabetes-related nerve damage.
The protective effects of GDNF in laboratory cells completely disappeared when researchers pharmacologically inhibited the PI3K/AKT signaling pathway, demonstrating this pathway is essential for GDNF’s therapeutic benefits.
GDNF treatment successfully mitigated endoplasmic reticulum stress and reactivated the suppressed PI3K/AKT signaling cascade in both the corneal epithelium and trigeminal ganglia of diabetic mice.
The Quick Take
- What they studied: Whether a protein called GDNF can repair eye damage caused by diabetes by reducing cellular stress and promoting healing
- Who participated: Human eye cells grown in laboratory conditions and diabetic mice created to mimic type 2 diabetes in humans
- Key finding: GDNF treatment restored the ability of damaged eye cells to grow and move, reduced cell death, and accelerated corneal healing in diabetic mice while restoring nerve sensitivity
- What it means for you: This research suggests a potential new treatment approach for diabetic eye disease, though human clinical trials are still needed before this therapy becomes available to patients
The Research Details
The researchers used two complementary approaches to test GDNF. First, they grew human corneal cells (the clear front layer of the eye) in laboratory dishes and exposed them to conditions that mimic diabetes, then treated some cells with GDNF to see if it helped them survive and function better. They also tested what happened when they blocked the specific cellular pathway they thought GDNF was using, to confirm that pathway was essential for the treatment to work.
Second, they created diabetic mice using a high-fat diet combined with a chemical injection to trigger diabetes similar to type 2 diabetes in humans. These mice developed eye damage similar to what diabetic patients experience. The researchers then injected GDNF directly under the conjunctiva (the membrane covering the white part of the eye) and measured whether the cornea healed faster, whether nerve endings regrew, and whether the mice regained normal eye sensitivity.
Throughout both experiments, the team measured specific proteins and examined cell structures using powerful microscopes to understand exactly how GDNF was working at the molecular level.
This research approach is important because it combines laboratory cell studies with living animal models, which helps confirm that findings in simple cell cultures actually work in a complex biological system. By testing whether blocking the PI3K/AKT pathway eliminated GDNF’s benefits, the researchers identified the specific mechanism responsible for the treatment’s effects, making the results more credible and actionable for future drug development.
This study demonstrates solid scientific methodology by using both in vitro (lab cell) and in vivo (living animal) models, which strengthens confidence in the findings. The researchers used multiple measurement techniques including protein analysis, microscopy, and functional tests of eye sensitivity and healing. However, the study was conducted in animals and laboratory conditions, so results may not directly translate to human patients. The specific sample sizes for animal experiments were not detailed in the abstract, which limits assessment of statistical power.
What the Results Show
GDNF treatment produced dramatic improvements in diabetic eye damage through multiple mechanisms. In laboratory-grown human eye cells exposed to diabetic conditions, GDNF restored the cells’ ability to multiply and migrate (move around), reduced the rate at which cells died, and decreased stress inside the cells’ endoplasmic reticulum (a cellular structure that processes proteins). These protective effects completely disappeared when researchers blocked the PI3K/AKT signaling pathway, proving this pathway was essential for GDNF’s benefits.
In diabetic mice, injecting GDNF under the eye produced even more impressive results. The corneal surface healed significantly faster compared to untreated diabetic mice. Nerve fibers that had been damaged by diabetes regrew and reconnected. Most importantly, the mice regained normal eye sensitivity, meaning they could feel touch and respond normally to stimuli that diabetic mice typically cannot sense due to nerve damage.
The researchers also examined the molecular changes occurring inside cells and found that GDNF reactivated the PI3K/AKT signaling pathway in both the corneal tissue and the trigeminal ganglia (nerve clusters that control eye sensation). This reactivation directly reduced the cellular stress that diabetes had caused.
The study revealed that endoplasmic reticulum stress, a type of cellular damage where protein-processing structures malfunction, is a key problem in diabetic eye disease. GDNF’s ability to reduce this specific type of stress appears to be central to its healing effects. The research also showed that nerve regeneration occurred alongside epithelial (surface tissue) healing, suggesting GDNF benefits multiple eye structures simultaneously rather than just one component.
This research builds on prior knowledge that GDNF is a growth factor that supports nerve cell survival and function. Previous studies suggested GDNF might help with diabetic nerve damage in other parts of the body, but this is among the first to demonstrate its specific benefits for diabetic eye disease and to identify the exact cellular pathway responsible. The focus on endoplasmic reticulum stress as a therapeutic target represents a newer understanding of how diabetes damages eye tissue.
The study was conducted entirely in laboratory cells and mice, not in human patients, so results may not translate directly to human treatment. The abstract does not specify the number of mice used or provide detailed statistical analysis, making it difficult to assess how reliable the findings are. The treatment was delivered by injection under the eye, which is more invasive than oral medication and may not be practical for all patients. Long-term effects and potential side effects of repeated GDNF injections were not evaluated. Additionally, the study focused on type 2 diabetes models, so results may differ in type 1 diabetes or other forms of eye disease.
The Bottom Line
Based on this research, GDNF shows promise as a potential treatment for diabetic eye damage, but it is not yet ready for human use. Confidence level: Moderate for the basic science findings, but low for clinical application until human trials are completed. Anyone with diabetic eye disease should continue following their doctor’s current treatment recommendations and discuss any new experimental therapies with their eye care specialist before considering participation in clinical trials.
This research is most relevant to people with type 2 diabetes who have or are at risk for diabetic eye disease (diabetic keratopathy or diabetic retinopathy). It may also interest researchers and ophthalmologists developing new treatments. People with type 1 diabetes should note that this study focused specifically on type 2 diabetes models. This research is not yet applicable to the general public but represents an important step toward future treatment options.
If GDNF moves forward to human clinical trials, it typically takes 5 to 10 years for a new treatment to progress from animal studies to FDA approval and availability to patients. Even if trials are successful, GDNF would likely first be available for severe cases of diabetic eye disease before becoming more widely used.
Frequently Asked Questions
Can GDNF treatment help people with diabetic eye disease right now?
GDNF is not yet available as a treatment for patients. This 2026 research demonstrates promising results in mice and laboratory cells, but human clinical trials are required before the FDA can approve it for medical use, which typically takes several more years.
How does GDNF repair diabetic eye damage?
GDNF works by activating a cellular pathway called PI3K/AKT that reduces endoplasmic reticulum stress, a type of damage diabetes causes inside cells. This reactivation allows damaged corneal cells to survive, grow, and migrate, while also stimulating nerve fiber regrowth and restoring eye sensitivity.
What is endoplasmic reticulum stress and why does diabetes cause it?
The endoplasmic reticulum is a cellular structure that processes and folds proteins. High blood sugar and excess fat from diabetes overwhelm this system, causing proteins to misfold and accumulate, creating cellular stress. This stress damages eye tissue and nerves, contributing to diabetic eye disease.
Will this treatment work for all types of diabetes?
This study specifically tested GDNF in a type 2 diabetes model. Results may differ in type 1 diabetes or other forms of eye disease. Future research would need to evaluate GDNF’s effectiveness across different diabetes types before drawing broader conclusions.
How would GDNF be delivered to patients if it becomes approved?
In this study, GDNF was injected directly under the conjunctiva (the membrane covering the eye). This injection approach may be the delivery method for future treatment, though researchers may also explore other delivery options like eye drops or oral medications.
Want to Apply This Research?
- Users with diabetes could track eye-related symptoms weekly: corneal sensitivity (how well they can feel their eye), vision clarity, and any eye discomfort or dryness. Rate each on a scale of 1 to 10 to monitor changes over time.
- While GDNF treatment is not yet available, users can take action now by maintaining tight blood sugar control through diet, exercise, and medication adherence, which slows diabetic eye damage. The app could send reminders for blood sugar monitoring and eye care appointments.
- Set up monthly check-ins to review eye health trends and blood sugar control patterns. Share this data with your eye doctor during regular appointments to catch any progression of diabetic eye disease early, before symptoms become severe.
This research describes experimental findings in laboratory cells and diabetic mice. GDNF is not currently approved by the FDA for treating diabetic eye disease in humans. This article is for educational purposes only and should not be interpreted as medical advice or a recommendation to seek GDNF treatment. Anyone with diabetic eye disease should consult with their ophthalmologist about current approved treatment options and discuss any interest in experimental therapies. Do not stop or change any current diabetes or eye care medications without consulting your healthcare provider.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.